magrolimab + carfilzomib + dexamethasone

Magrolimab + carfilzomib + dexamethasone is a combination investigational regimen for the treatment of relapsed/refractory multiple myeloma. **Magrolimab** is a first-in-class humanized monoclonal antibody that targets CD47, a 'do not eat me' signal, thereby promoting macrophage-mediated phagocytosis of tumor cells. **Carfilzomib** is a second-generation irreversible proteasome inhibitor that induces apoptosis in myeloma cells. **Dexamethasone** is a synthetic glucocorticoid that enhances antimyeloma effects and mitigates treatment-related inflammation. The combination aims to exploit the synergistic effects of immunotherapy (via CD47 blockade) and targeted cytotoxic therapy. This regimen is under investigation in phase II studies for patients who have persistent disease after standard therapies. Primary developer is Gilead Sciences (for magrolimab); Amgen (for carfilzomib); dexamethasone is generic[1][2][5].